First-in-human Study of Mivebresib (ABBV-075), an Oral Pan-inhibitor of Bromodomain and Extra Terminal Proteins, in Patients with Relapsed/Refractory Solid Tumors.

CONCLUSIONS: Based on safety and tolerability, mivebresib RP2D is 1.5mg for the daily schedule, 2.5mg for 4/7 and 3mg for M-W-F. Mivebresib has a tolerable safety profile and stable disease was observed in some patients with malignant solid tumors.
PMID: 31420359 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - August 15, 2019 Category: Cancer & Oncology Authors: Piha-Paul SA, Sachdev JC, Barve M, LoRusso PM, Szmulewitz RZ, Patel SP, Lara PN, Chen X, Hu B, Freise KJ, Modi D, Sood A, Hutti JE, Wolff J, O'Neil BH Tags: Clin Cancer Res Source Type: research